Overseen ByEugenio Cersosimo, MD,PhD
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 4
Waitlist Available
Sponsor: The University of Texas Health Science Center at San Antonio
Prior Safety Data
Breakthrough Therapy
Approved in 3 jurisdictions
Trial Summary
What is the purpose of this trial?This trial investigates how dapagliflozin, a drug that helps remove excess sugar through urine, affects glucose production in the liver and kidneys. The study involves people with type 2 diabetes and healthy individuals. Researchers aim to determine whether the liver or kidneys are responsible for increased glucose production when using this medication.
Eligibility Criteria
Participant Groups
4Treatment groups
Active Control
Placebo Group
Group I: T2DM individuals on DapagliflozinActive Control1 Intervention
Individuals with type 2 diabetes mellitus - dapagliflozin
Group II: Normal Glucose Tolerance (NGT) on DapagliflozinActive Control1 Intervention
Individuals with normal glucose tolerance - dapagliflozin
Group III: T2DM individuals on PlaceboPlacebo Group1 Intervention
Individuals with type 2 diabetes mellitus on placebo
Group IV: Normal Glucose Tolerance (NGT) PlaceboPlacebo Group1 Intervention
Individuals with normal glucose tolerance - on placebo
Dapagliflozin is already approved in European Union, United States, Canada for the following indications:
🇪🇺 Approved in European Union as Forxiga for:
- Type 2 diabetes
- Heart failure
- Chronic kidney disease
🇺🇸 Approved in United States as Farxiga for:
- Type 2 diabetes
- Heart failure
- Chronic kidney disease
🇨🇦 Approved in Canada as Farxiga for:
- Type 2 diabetes
- Heart failure
- Chronic kidney disease
Find A Clinic Near You
Research locations nearbySelect from list below to view details:
University of Texas Health Science CenterSan Antonio, TX
Loading ...
Who is running the clinical trial?
The University of Texas Health Science Center at San AntonioLead Sponsor
AstraZenecaIndustry Sponsor